Aflac Incorporated — 2020 Form 10-K Summary
Business context and reporting period
Period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter filing. Aflac sells supplemental health and life insurance, principally in Japan and the United States. Japan accounted for 68% of 2020 revenue and 83% of year-end assets.
Financial results and position
- Revenue: $22.1 billion, down 0.7% from $22.3 billion in 2019. Net premiums were $18.6 billion, down 0.8%; net investment income was $3.6 billion, up 1.7%.
- Earnings: GAAP net earnings were $4.8 billion ($6.67 diluted EPS), versus $3.3 billion ($4.43) in 2019. The increase chiefly reflects a one-time $1.4 billion tax benefit from releasing deferred foreign tax credit valuation allowances. Adjusted earnings, a non-GAAP measure, were $3.6 billion ($4.96 diluted EPS), versus $3.3 billion ($4.44).
- Investment results: Pretax net investment losses were $270 million, compared with $135 million in 2019. They included $200 million of credit losses. Management said pandemic-related realized losses, impairments and credit losses were not material to results overall.
- Segment profitability: Pretax adjusted earnings were $3.263 billion in Japan (approximately flat) and $1.268 billion in the U.S. ($1.272 billion in 2019). Pretax adjusted profit margins were 21.2% in Japan and 19.3% in the U.S., each slightly below 2019.
- Cash flow: Operating cash flow was $6.0 billion, up from $5.5 billion. Investing activities used $4.6 billion and financing activities used $1.1 billion. Year-end cash and cash equivalents were $5.1 billion.
- Balance sheet and debt: Total assets were $165.1 billion, policy liabilities $114.4 billion, notes payable and lease obligations $7.9 billion, and shareholders’ equity $33.6 billion. Equity included $10.3 billion of net unrealized investment gains and derivatives.
- Capital and shareholder returns: Japan solvency margin ratio was 960% (1,043% in 2019); U.S. combined RBC ratio was 550%. Aflac repurchased $1.5 billion of shares and paid $769 million in cash dividends. The company announced a 17.9% increase in the first-quarter 2021 dividend.
Material changes versus 2019
- COVID-19 and related restrictions sharply reduced new annualized premium sales: Japan down 36.2% in yen and the U.S. down 30.8%. Sales weakness was compounded in Japan by the continuing effects of the Japan Post investigation.
- Lower routine medical utilization reduced claims during 2020; pandemic-related claims and reserve increases were more than offset by reduced routine claims. U.S. benefit ratios fell for the year, while management noted some recovery in the second half.
- Japan adjusted net investment income rose to $2.659 billion from $2.496 billion, while U.S. adjusted net investment income fell to $705 million from $720 million. New-money yields declined in both segments.
- Expenses rose, including technology and platform investments, Argus-related costs and a $43 million fourth-quarter severance charge. The company also issued $1.0 billion of U.S. senior notes and ¥57.0 billion of yen senior notes in 2020.
Outlook, risks and unusual items
- 2021 outlook: Management expects 2021 U.S. profit margins to decline as benefit ratios normalize, expenses remain elevated and pandemic-related sales pressure continues. For 2020–2022, it forecasts Japan revenue CAGR of negative 2.0% to negative 3.0%, and U.S. revenue CAGR ranging from negative 1.0% to positive 1.5%. It targets a minimum Japan SMR of 500% and U.S. RBC of approximately 400%.
- COVID-19 and distribution: The duration and economic effects of the pandemic remain uncertain. Face-to-face sales and agent recruiting were disrupted; premium grace periods, unemployment and small-business exposure may affect future lapses, sales and persistency.
- Japan Post: Japan Post channel sales remained materially depressed after the investigation and related business suspension. A return to 2018 sales levels was not expected in the near term; the timing and longer-term effects were uncertain.
- Investment and currency risks: Low interest rates, credit downgrades/defaults, limited long-dated yen investments, JGB concentration, and yen-dollar movements may affect earnings, capital, liquidity and subsidiary dividend capacity. Japan represents a substantial share of the business and investment portfolio.
- Accounting change: The long-duration insurance accounting standard, effective for Aflac after December 15, 2022, is expected to materially affect reported results, equity and disclosures, including greater quarterly earnings and AOCI volatility. Management does not expect adoption to affect cash flows or regulatory capital.
- Other items and contingencies: The company acquired Zurich North America’s U.S. Corporate Life and Pensions business for $140 million and acquired an approximately 9% stake in Trupanion for about $200 million. It reported routine-course lawsuits and said their expected outcome was not material; results remain uncertain. COVID-related loan modifications had no material impact on results at year-end. The filing reports no material off-balance-sheet letters of credit, guarantees or standby repurchase obligations.
Important facts for investors to verify
- Separate recurring operating performance from the $1.4 billion tax benefit; review adjusted earnings reconciliation and the assumptions behind future tax-credit realization.
- Track Japan Post channel recovery, pandemic-era sales trends, premium persistency and lapse rates in both markets.
- Monitor investment credit quality, expected credit-loss allowances, private-asset valuations, new-money yields and exposure to Japan government bonds.
- Assess liquidity and holding-company access to subsidiary dividends, including currency-hedge collateral needs, debt maturities and the effect of market movements on SMR and RBC.
- Review the assumptions and implementation impact of the long-duration insurance accounting standard as adoption approaches.